Fig. 2From: Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)Distribution of day 3 positivity after treatment with artemisinin-based combination therapy (ACT) and molecular markers (k13, pfarps10, pffd and pfmdr2) in six sentinel sites. Day 3 prevalence and high mutant rate of molecular markers were observed in southern Myanmar sites, Myanmar Artemisinin Resistance Containment (MARC) Tier I areasBack to article page